Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NEORx VERLUMA IMAGING AGENT FOR INITIAL STAGING OF SMALL CELL LUNG CANCER ACCURATE IN 82% OF PATIENTS; GAINS RECOMMENDATION FROM FDA COMMITTEE.

Executive Summary

NeoRx' monoclonal antibody imaging agent Verluma (technetium 99m nofetumomab merpentan) accurately staged 73 of 89 small cell lung cancer patients with a positive biopsy (82%) compared to 80 of 89 (90%) with the standard battery of tests, leading FDA's Oncologic Drugs Advisory Committee to recommend the diagnostic for approval for initial staging of SCLC in a 9-4 vote Dec. 14.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027395

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel